AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32609374 — intervention group
Group type: COMPARATOR
Intervention: Comparison of intrauterine tamponade methods (Bakri balloon vs condom catheter)
Number of subjects: 944
Study 32609374 — intervention group
Group type: COMPARATOR
Intervention: Comparison of intrauterine tamponade methods (Bakri balloon vs gauze packing)
Number of subjects: 944
Study 32609374 — intervention group
Group type: COMPARATOR
Intervention: Modified B-Lynch compression suture
Number of subjects: 944
Study 32609959 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Number of subjects: 0
Study 32610059 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS-PCP (primary care physician endorsed SMS)
Number of subjects: 14438
Study 32610059 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS-PCP
Number of subjects: 14438
Study 32610059 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS (no manipulation)
Number of subjects: 14438
Study 32610059 — intervention group
Group type: COMPARATOR
Intervention: Control (no SMS)
Number of subjects: 14438
Study 32610581 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimasertib
Number of subjects: 0
Study 32610581 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine
Number of subjects: 0
Study 32611221 — intervention group
Group type: EXPERIMENTAL
Intervention: Spring
Number of subjects: 1113
Study 32611221 — intervention group
Group type: EXPERIMENTAL
Intervention: Summer
Number of subjects: 1113
Study 32611221 — intervention group
Group type: EXPERIMENTAL
Intervention: Autumn
Number of subjects: 1113
Study 32611221 — intervention group
Group type: EXPERIMENTAL
Intervention: Winter
Number of subjects: 1113
Study 32611374 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-200 family (miR-200a, miR-200b, miR-200c) isolated from tumor tissue and plasma
Number of subjects: 16
Study 32611374 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-200 family isolated from urine
Number of subjects: 16
Study 32611374 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of miRNA-200 expression in urine and plasma
Number of subjects: 16
Study 32611374 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma and urine for miRNA detection
Number of subjects: 16
Study 32611397 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional pain management
Number of subjects: 19
Study 32611546 — intervention group
Group type: EXPERIMENTAL
Intervention: RTI risk assessment screening tool
Number of subjects: 303
Study 32611608 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting serum fructose levels
Number of subjects: 949
Study 32611608 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting serum fructose levels (after adjustment for additional factors)
Number of subjects: 949
Study 32611642 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI with short TI inversion recovery to identify regions of interest (ROIs) with hyperintensities indicating muscle inflammation
Number of subjects: 10
Study 32611642 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle T2 relaxation time mapping as a quantitative marker of muscle inflammation
Number of subjects: 10
Study 32611642 — intervention group
Group type: EXPERIMENTAL
Intervention: Dixon sequences to quantify muscle fat replacement
Number of subjects: 10
Study 32611642 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls examined with a magnetic resonance scan once for determination of normal values of T2 relaxation time
Number of subjects: 10
Study 32611662 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse drug reactions in patients with CKD
Number of subjects: 3033
Study 32611662 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific pharmacologic classes (antithrombotic agents)
Number of subjects: 3033
Study 32611728 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose of alteplase
Number of subjects: 3479
Study 32611728 — intervention group
Group type: COMPARATOR
Intervention: Standard dose of alteplase
Number of subjects: 3479
Study 32611729 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced MRI (DCE-MRI) before and 6 months after endovascular treatment
Number of subjects: 80
Study 32611729 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative analysis of the vasa vasorum in the IMH
Number of subjects: 80
Study 32611739 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy-naïve patients receiving standard PIBD care with follow-up up to 20 years.
Number of subjects: 0
Study 32611739 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive immunological analyses including blood samples and intestinal biopsies.
Number of subjects: 0
Study 32611743 — intervention group
Group type: EXPERIMENTAL
Intervention: RaceRunning intervention (one session each week for 24 weeks)
Number of subjects: 25
Study 32611742 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal questionnaire survey
Number of subjects: 902
Study 32611742 — intervention group
Group type: EXPERIMENTAL
Intervention: Data from population-based registries
Number of subjects: 902
Study 32611745 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of a patient-reported outcome (PRO) tool for measuring flare in IBD based on messages from an internet forum.
Number of subjects: 0
Study 32612255 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine-based regimen with rituximab
Number of subjects: 42
Study 32612255 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine-based regimen without rituximab
Number of subjects: 42
Study 32612522 — intervention group
Group type: EXPERIMENTAL
Intervention: SMR/Theta Neurofeedback Training
Number of subjects: 0
Study 32612576 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary exosomal thyroglobulin measurement
Number of subjects: 0
Study 32612737 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal provocation test with house dust mite (HDM)
Number of subjects: 131
Study 32612737 — intervention group
Group type: COMPARATOR
Intervention: Total IgE and house dust mite specific IgE
Number of subjects: 131
Study 32612737 — intervention group
Group type: COMPARATOR
Intervention: Nasal IgE to HDM allergens
Number of subjects: 131
Study 32612738 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick testing with a panel of 12 allergens
Number of subjects: 1671
Study 32612738 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick testing
Number of subjects: 1671
Study 32613082 — intervention group
Group type: EXPERIMENTAL
Intervention: dlPFC stimulation by iTBS alone
Number of subjects: 40
Study 32613082 — intervention group
Group type: EXPERIMENTAL
Intervention: dlPFC stimulation by iTBS while simultaneously performing a cognitive task
Number of subjects: 40
Study 32613082 — intervention group
Group type: COMPARATOR
Intervention: vertex (control) iTBS stimulation
Number of subjects: 40
Study 32613089 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose lung irradiation (LD-RT) combined with pharmacological treatment
Number of subjects: 106
Study 32613089 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological treatment only
Number of subjects: 106
Study 32613089 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose lung irradiation (LD-RT)
Number of subjects: 106
Study 32613319 — intervention group
Group type: EXPERIMENTAL
Intervention: Turner syndrome (TS) group
Number of subjects: 168
Study 32613319 — intervention group
Group type: COMPARATOR
Intervention: Control group (without TS)
Number of subjects: 168
Study 32613402 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental formula with high beta-PA (20-25%) from cow's milk fat and 0.5 g GOS/100 ml
Number of subjects: 0
Study 32613402 — intervention group
Group type: COMPARATOR
Intervention: Standard infant formula with low beta-PA (< 10%) without prebiotics
Number of subjects: 0
Study 32613402 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-fed reference group
Number of subjects: 0
Study 32613402 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study 32614159 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib
Number of subjects: 54
Study 32614327 — intervention group
Group type: EXPERIMENTAL
Intervention: Triaxial accelerometer sensor placed on the anterior chest to monitor body positions 24-hours daily through a 4-week monitoring period.
Number of subjects: 2
Study 32614379 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal iron absorption accounting for iron transferred to the fetus
Number of subjects: 68
Study 32614379 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal iron absorption accounting for iron retained within the placenta
Number of subjects: 68
Study 32614379 — intervention group
Group type: EXPERIMENTAL
Intervention: Net transfer of iron to the neonate
Number of subjects: 68
Study 32614379 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal hepcidin
Number of subjects: 68
Study 32614391 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrone (E1)
Number of subjects: 5325
Study 32614391 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (E2)
Number of subjects: 5325
Study 32614391 — intervention group
Group type: COMPARATOR
Intervention: Undetectable E2 vs detectable E2
Number of subjects: 5325
Study 32614391 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear regression model including age, BMI, E1, and testosterone
Number of subjects: 5325
Study 32614451 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Diagnostic Tests (RDTs) for HCV detection in HIV-uninfected samples (n=384)
Number of subjects: 1710
Study 32614451 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Diagnostic Tests (RDTs) for HCV detection in HIV-infected samples (n=264)
Number of subjects: 1710
Study 32614698 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrotinib monotherapy
Number of subjects: 60
Study 32614702 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel-based chemotherapy
Number of subjects: 2887
Study 32614702 — intervention group
Group type: COMPARATOR
Intervention: Non-docetaxel-based chemotherapy
Number of subjects: 2887
Study 32614835 — intervention group
Group type: EXPERIMENTAL
Intervention: FLAIR post-contrast MRI
Number of subjects: 25
Study 32614835 — intervention group
Group type: COMPARATOR
Intervention: T1 weighted imaging (T1WI) post-contrast MRI
Number of subjects: 25
Study 32614963 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-free remission (TFR) after stopping tyrosine kinase inhibitors (TKIs)
Number of subjects: 128
Study 32614963 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with fluctuating minimal residual disease (MRD)
Number of subjects: 128
Study 32614963 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with stable MRD
Number of subjects: 128
Study 32614963 — intervention group
Group type: EXPERIMENTAL
Intervention: Late molecular recurrences (LMRec) after 2 years in TFR
Number of subjects: 128
Study 32614963 — intervention group
Group type: EXPERIMENTAL
Intervention: MRec after 2 years in TFR
Number of subjects: 128
Study 32614963 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall MRec
Number of subjects: 128
Study 32615102 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton beam radiotherapy
Number of subjects: 0
Study 32615102 — intervention group
Group type: COMPARATOR
Intervention: Photon beam radiotherapy
Number of subjects: 0
Study 32615108 — intervention group
Group type: EXPERIMENTAL
Intervention: Avapritinib (300 mg recommended phase 2 dose, administered orally once daily)
Number of subjects: 82
Study 32615108 — intervention group
Group type: EXPERIMENTAL
Intervention: Avapritinib (varied doses from 30 mg to 600 mg)
Number of subjects: 82
Study 32615108 — intervention group
Group type: EXPERIMENTAL
Intervention: Avapritinib (600 mg)
Number of subjects: 82
Study 32615108 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum tolerated dose of Avapritinib
Number of subjects: 82
Study 32615108 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended phase 2 dose of Avapritinib
Number of subjects: 82
Study 32615192 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental treadmill cardiopulmonary exercise test
Number of subjects: 35
Study 32615331 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerindocianine sodium (0.06 mg/kg, 0.12 mg/kg, 0.045 mg/kg)
Number of subjects: 41
Study 32615331 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerindocianine sodium (0.06 mg/kg)
Number of subjects: 41
Study 32615331 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerindocianine sodium
Number of subjects: 41
Study 32615649 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients on insulin
Number of subjects: 209
Study 32615649 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients not on insulin
Number of subjects: 209
Study 32615649 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-diabetic patients
Number of subjects: 209
Study 32615649 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-diabetic patients with pre-operative HbA1c < 42 mmol/mol and random plasma glucose < 7.8 mmol/l
Number of subjects: 209
Study 32615649 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient population
Number of subjects: 209
Study 32615968 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified method for neuraxial anesthesia
Number of subjects: 518
Study 32615968 — intervention group
Group type: COMPARATOR
Intervention: Conventional method for neuraxial anesthesia
Number of subjects: 518
Study 32616009 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat Soy Blend (WSB)
Number of subjects: 800
Study 32616009 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based Nutrient Supplement (LNS)
Number of subjects: 800
Study 32616009 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient powder (MNP)
Number of subjects: 800
Study 32616009 — intervention group
Group type: EXPERIMENTAL
Intervention: General food supplementation program
Number of subjects: 800
Study 32616009 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Workers (CHWs) interaction
Number of subjects: 800
Study 32616154 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32616162 — intervention group
Group type: EXPERIMENTAL
Intervention: Citizen responders arriving before EMS
Number of subjects: 438
Study 32616162 — intervention group
Group type: COMPARATOR
Intervention: OHCAs where EMS arrived first
Number of subjects: 438
Study 32616493 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered questionnaires
Number of subjects: 375
Study 32616493 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociodemographic, health status, workplace information, work commuting information, driving behaviour, history of RCI
Number of subjects: 375
Study 32616493 — intervention group
Group type: EXPERIMENTAL
Intervention: Checklist of Individual Strength Questionnaire
Number of subjects: 375
Study 32616493 — intervention group
Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index
Number of subjects: 375
Study 32616493 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-item Depression Anxiety and Stress Scale
Number of subjects: 375
Study 32616493 — intervention group
Group type: EXPERIMENTAL
Intervention: Utrecht's Work Engagement Scale
Number of subjects: 375
Study 32616499 — intervention group
Group type: EXPERIMENTAL
Intervention: Early progressive disease (PD; time to progression, TTP ≤18 months)
Number of subjects: 926
Study 32616499 — intervention group
Group type: EXPERIMENTAL
Intervention: Late progressive disease (TTP >18 months)
Number of subjects: 926
Study 32616499 — intervention group
Group type: EXPERIMENTAL
Intervention: No progressive disease
Number of subjects: 926
Study 32616499 — intervention group
Group type: EXPERIMENTAL
Intervention: At least very good partial response rate
Number of subjects: 926
Study 32616515 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ASN008 gel
Number of subjects: 0
Study 32616515 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ASN008 gel (once-daily application for 5 days)
Number of subjects: 0
Study 32616555 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide plus pembrolizumab (200 mg IV every 3 weeks for four doses)
Number of subjects: 28
Study 32616555 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide plus pembrolizumab
Number of subjects: 28
Study 32616557 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutathera 3.7 GBq every 8 weeks for four doses with nivolumab 240 mg every 2 weeks
Number of subjects: 9
Study 32616557 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutathera 7.4 GBq every 8 weeks for four doses with nivolumab 240 mg every 2 weeks
Number of subjects: 9
Study 32616557 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutathera plus nivolumab
Number of subjects: 9
Study 32616759 — intervention group
Group type: EXPERIMENTAL
Intervention: Single infusion of autologous umbilical cord blood
Number of subjects: 0
Study 32616802 — intervention group
Group type: EXPERIMENTAL
Intervention: EuroScore 2
Number of subjects: 4980
Study 32616802 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP
Number of subjects: 4980
Study 32616802 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model of EuroScore 2 and BNP
Number of subjects: 4980
Study 32616867 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment (three monthly injections followed by PRN regimen)
Number of subjects: 32
Study 32617173 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention designed for psychiatric PTSD patients as a therapy add-on
Number of subjects: 0
Study 32617173 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32617429 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) targeting sitting balance for 30-45 min daily for 10-12 sessions
Number of subjects: 76
Study 32617429 — intervention group
Group type: COMPARATOR
Intervention: Virtual reality (VR) with limited arm movement for 30-45 min daily for 10-12 sessions
Number of subjects: 76
Study 32617435 — intervention group
Group type: EXPERIMENTAL
Intervention: Body therapy treatment as add-on to treatment as usual
Number of subjects: 42
Study 32617435 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 42
Study 32617453 — intervention group
Group type: EXPERIMENTAL
Intervention: Multistrain probiotic (4 capsules of Vivomixx)
Number of subjects: 50
Study 32617453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 32617453 — intervention group
Group type: EXPERIMENTAL
Intervention: Multistrain probiotic
Number of subjects: 50
Study 32617528 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-In Treatment Approach
Number of subjects: 20
Study 32617528 — intervention group
Group type: COMPARATOR
Intervention: Opt-Out Treatment Approach
Number of subjects: 20
Study 32617582 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (1 g each, two courses, 2 weeks apart at the beginning and again at 6 months)
Number of subjects: 11
Study 32617641 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallium-68-labelled somatostatin analogue (SSA) PET
Number of subjects: 12
Study 32617641 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorine-18-labelled alternative
Number of subjects: 12
Study 32617919 — intervention group
Group type: EXPERIMENTAL
Intervention: ORBERA® Intragastric Balloon System (IGB) as an adjunct to lifestyle intervention
Number of subjects: 258
Study 32618009 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT for ≤12 months post discharge
Number of subjects: 12922
Study 32618009 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT for >12 months post discharge
Number of subjects: 12922
Study 32618009 — intervention group
Group type: COMPARATOR
Intervention: Not on DAPT at 12 months
Number of subjects: 12922
Study 32618282 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32618486 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbital Atherectomy
Number of subjects: 0
Study 32618486 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32618572 — intervention group
Group type: EXPERIMENTAL
Intervention: Rose app intervention
Number of subjects: 30
Study 32618572 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 30
Study 32618687 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid response electroencephalography
Number of subjects: 181
Study 32618884 — intervention group
Group type: EXPERIMENTAL
Intervention: empagliflozin 10 mg or 25 mg
Number of subjects: 7020
Study 32618884 — intervention group
Group type: EXPERIMENTAL
Intervention: empagliflozin
Number of subjects: 7020
Study 32618884 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7020
Study 32619006 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterus transplantation (UTx)
Number of subjects: 9
Study 32619039 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid
Number of subjects: 9469
Study 32619039 — intervention group
Group type: COMPARATOR
Intervention: Colloid
Number of subjects: 9469
Study 32619039 — intervention group
Group type: COMPARATOR
Intervention: Ephedrine
Number of subjects: 9469
Study 32619039 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron
Number of subjects: 9469
Study 32619039 — intervention group
Group type: COMPARATOR
Intervention: Lower limb compression
Number of subjects: 9469
Study 32619039 — intervention group
Group type: COMPARATOR
Intervention: Walking
Number of subjects: 9469
Study 32619077 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib plus letrozole (600 mg for Asian non-Japanese patients; 300 mg for Japanese patients)
Number of subjects: 0
Study 32619077 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib plus endocrine therapy
Number of subjects: 0
Study 32619077 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib combined with endocrine therapy
Number of subjects: 0
Study 32619115 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab, a CD19 BiTE, administered to adults with MRD BCP-ALL after chemotherapy.
Number of subjects: 0
Study 32619621 — intervention group
Group type: EXPERIMENTAL
Intervention: Total inflow and outflow vascular clamping (study group)
Number of subjects: 230
Study 32619621 — intervention group
Group type: COMPARATOR
Intervention: Inflow and outflow vascular clamping only of the segment harboring the tumor (control group)
Number of subjects: 230
Study 32619740 — intervention group
Group type: EXPERIMENTAL
Intervention: Common genetic variants near SCN5A/SCN10A
Number of subjects: 586
Study 32619740 — intervention group
Group type: EXPERIMENTAL
Intervention: Common variants near HEY2
Number of subjects: 586
Study 32619740 — intervention group
Group type: EXPERIMENTAL
Intervention: Rare and low-frequency variants
Number of subjects: 586